Teriparatide

What is Teriparatide?#

Teriparatide is a recombinant form of human parathyroid hormone consisting of the first 34 N-terminal amino acids (PTH(1-34)), which represent the biologically active region of the full 84-amino-acid PTH molecule. Developed by Eli Lilly and marketed as Forteo, teriparatide was FDA-approved in November 2002 as the first osteoanabolic (bone-forming) agent for the treatment of osteoporosis.

Teriparatide is manufactured using recombinant DNA technology in a strain of Escherichia coli. It has an identical amino acid sequence to the N-terminal 34 residues of endogenous human PTH, ensuring native receptor binding and signaling properties.

Teriparatide is indicated for:

• Postmenopausal osteoporosis: Women at high risk for fracture, defined as history of osteoporotic fracture, multiple risk factors, or failure/intolerance of other osteoporosis therapy
• Male osteoporosis: Men with primary or hypogonadal osteoporosis at high risk for fracture
• Glucocorticoid-induced osteoporosis (GIO): Men and women with osteoporosis associated with sustained systemic glucocorticoid therapy at high risk for fracture

Mechanism of Action#

Teriparatide acts by binding to the parathyroid hormone 1 receptor (PTH1R), a G protein-coupled receptor expressed on osteoblasts, osteocytes, and renal tubular cells. The therapeutic effect depends critically on the pattern of exposure:

Intermittent vs. Continuous Exposure#

• Intermittent (pulsatile) exposure: Daily subcutaneous injection produces a brief peak in PTH(1-34) levels lasting 4-6 hours, followed by clearance. This pulsatile pattern preferentially stimulates osteoblast proliferation, differentiation, and survival while having a lesser effect on osteoclast activation. The net result is increased bone formation exceeding resorption -- the anabolic window.

• Continuous exposure: Sustained PTH elevation (as in primary hyperparathyroidism) activates both osteoblasts and osteoclasts, with the catabolic (resorptive) effects predominating, leading to net bone loss particularly at cortical sites. This is why continuous PTH excess causes osteoporosis rather than preventing it.

Key Signaling Pathways#

Upon PTH1R activation, teriparatide stimulates:

• cAMP/protein kinase A (PKA) pathway: primary signaling cascade driving osteoblast differentiation
• Wnt/beta-catenin pathway activation: promotes osteoblast proliferation and inhibits osteoblast apoptosis
• Downregulation of sclerostin: reduces osteocyte-derived inhibition of bone formation
• RANKL modulation: complex effects on osteoclast recruitment depending on exposure pattern

Research Overview#

Teriparatide has the most extensive long-term evidence base of any osteoanabolic agent, spanning over 20 years of clinical experience. The pivotal Fracture Prevention Trial demonstrated 65% reduction in vertebral fractures and 53% reduction in nonvertebral fractures. Teriparatide was subsequently shown to be superior to alendronate for glucocorticoid-induced osteoporosis, making it the only osteoanabolic with formal GIO approval.

The 2020 removal of the osteosarcoma boxed warning, based on 18 years of post-marketing surveillance data, was a landmark regulatory decision that eliminated the 2-year treatment duration limit.

Important Considerations#

• Prescription medication requiring medical supervision
• No longer limited to 2 years of cumulative use (boxed warning removed 2020)
• Most common adverse effects are hypercalcemia, dizziness, leg cramps, and nausea
• Contraindicated in patients with Paget disease, unexplained alkaline phosphatase elevation, open epiphyses, prior skeletal radiation, or pre-existing hypercalcemia
• Should be followed by antiresorptive therapy to maintain BMD gains
• Biosimilar versions available, improving cost accessibility

Key Research Findings#

Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis, published in New England Journal of Medicine (Neer RM et al., 2001; PMID: 11346808):

• The study showed vertebral fracture risk reduction of 65% with 20 mcg
• The study showed nonvertebral fracture risk reduction of 53% with 20 mcg
• The study showed lumbar spine BMD increase of 9% at 21 months with 20 mcg
• The study showed femoral neck BMD increase of 3% at 21 months with 20 mcg

Teriparatide or Alendronate in Glucocorticoid-Induced Osteoporosis, published in New England Journal of Medicine (Saag KG et al., 2007; PMID: 18003959):

• The study showed lumbar spine BMD of 7.2% teriparatide vs +3.4% alendronate
• The study showed vertebral fractures of 0.6% teriparatide vs 6.1% alendronate

Related Reading#

• Teriparatide research studies and evidence
• Teriparatide dosing protocols
• Teriparatide side effects profile
• Abaloparatide research guide